US Patent

US12447156 — Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors

Method of Use · Assigned to Albireo AB · Expires 2041-11-12 · 15y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating progressive familial intrahepatic cholestasis (PFIC) with an IBAT inhibitor such as odevixibat.

USPTO Abstract

Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.

Drugs covered by this patent

Bylvay (ODEVIXIBAT) · Ipsen

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3186`	—	Bylvay
`U-3186`	—	Bylvay
`U-3186`	—	Bylvay
`U-3186`	—	Bylvay

Patent Metadata

Patent number: US12447156
Jurisdiction: US
Classification: Method of Use
Expires: 2041-11-12
Drug substance claim: No
Drug product claim: No
Assignee: Albireo AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.